Application Note: Combining Large Scale Biochemical and Cellular Profiling Data to Better Understand the Mechanism of Anti-Tumor Drugs
22 July 2013

This poster is about elucidating the selectivity and cellular behavior of several marketed kinase inhibitors used in the treatment of cancer patients. Generally, kinase inhibitors are optimized to inhibit a single cellular target associated with cancer progression. However, most currently marketed kinase inhibitors interact with a highly conserved ATP binding site raising the question of their selectivity and therapeutic mechanism of action. Through EMD-Millipore’s KinaseProfiler™ service, the selectivity of Imatinib, Sunitinib, Lapatinib was profiled, as well as several other marketed kinase inhibitors against a panel of over 250 kinases.

Download PDF >>PDF Icon

Read the full article...

  Become a member
  • Quick and complete access to all application articles

  • Download 10,000+
    applications and methods

  • Make informed buying decisions


Already a member?

Log in for full access to the article




Remember me